The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  title={The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.},
  author={Bertram Pitt and Faiez Zannad and Willem J. Remme and Robert J. Cody and Alain Castaigne and A. P{\'e}rez and Jolie Palensky and Janet Turk Wittes},
  journal={The New England journal of medicine},
  volume={341 10},
BACKGROUND AND METHODS Aldosterone is important in the pathophysiology of heart failure. In a doubleblind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin. A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was… 

Figures and Tables from this paper

Effects of Spironolactone on Long-term Mortality and Morbidity in Patients With Heart Failure and Mild or No Symptoms

Administration of spironolactone reduced the composite of death and cardiovascular hospitalization in patients with NYHA classes I to II HF, suggesting that spironOLactone could be beneficial when administered on top of optimal therapy among patients with HF and mild or no symptoms.

Spironolactone for heart failure with preserved ejection fraction.

In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure.

Effect of carvedilol on survival in severe chronic heart failure.




The effect of digoxin on mortality and morbidity in patients with heart failure.

Digoxin did not reduce overall mortality, but it reduced the rate of hospitalization both overall and for worsening heart failure, which defines more precisely the role of digoxin in the management of chronic heart failure.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic congestive heart failure and reduced ejection fractions.

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor.

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.

There is a pronounced but variable neurohormonal activation in heart failure even in patients with similar clinical findings, and the effect of enalapril on mortality is related to hormonal activation in general and the renin-angiotensin system in particular.

Captopril in heart failure. A double blind controlled trial.

Captopril seemed to be of considerable value in the long term treatment of severe cardiac failure in a double blind trial.